141 related articles for article (PubMed ID: 38376572)
1. A case of acute promyelocytic leukemia with pericardial effusion successfully managed with colchicine during ATO administration.
Goto T; Nakamura N; Suzaki T; Shimazu R; Kaneda Y; Ikoma Y; Matsumoto T; Nakamura H; Kanemura N; Shimizu M
Ann Hematol; 2024 Apr; 103(4):1409-1410. PubMed ID: 38376572
[No Abstract] [Full Text] [Related]
2. Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?
Vassilakopoulos TP; Asimakopoulos JV; Plata E; Kelepesis G; Petevi K; Koutsi C; Papageorgiou L; Tsaftaridis P; Angelopoulou MK; Konstantopoulos K; Meletis J
Leuk Lymphoma; 2017 Jul; 58(7):1743-1746. PubMed ID: 27919176
[No Abstract] [Full Text] [Related]
3. Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia.
Freyer CW; Peterson CE; Man Y; Przespolewski A; Baron J; Luger SM
Leuk Lymphoma; 2021 Mar; 62(3):696-702. PubMed ID: 33106056
[TBL] [Abstract][Full Text] [Related]
4. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia.
Au WY; Kumana CR; Kou M; Mak R; Chan GC; Lam CW; Kwong YL
Blood; 2003 Jul; 102(1):407-8. PubMed ID: 12814916
[No Abstract] [Full Text] [Related]
5. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
6. Guest editorial: acute promyelocytic leukemia: change from "highly fatal to highly curable" leukemia.
Komatsu N
Int J Hematol; 2014 Jul; 100(1):16-7. PubMed ID: 24912657
[No Abstract] [Full Text] [Related]
7. Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse.
Kulkarni UP; Selvarajan S; Fouzia NA; Lionel S; Nair SC; Balasubramanian P; Mani T; Abraham A; George B; Mathews V
Blood Cancer J; 2023 Jun; 13(1):94. PubMed ID: 37349334
[No Abstract] [Full Text] [Related]
8. Mitochondrial myopathy caused by arsenic trioxide therapy.
Echaniz-Laguna A; Benoilid A; Vinzio S; Fornecker LM; Lannes B; Goullé JP; Broly F; Mousson de Camaret B
Blood; 2012 May; 119(18):4272-4. PubMed ID: 22427206
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax for arsenic-resistant acute promyelocytic leukaemia.
Wang QQ; Wang HF; Zhao JZ; Naranmandura H; Jin J; Zhu HH
Br J Haematol; 2022 Jun; 197(5):e58-e60. PubMed ID: 35176809
[No Abstract] [Full Text] [Related]
10. Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients.
Jen WY; Sasaki K; Rausch CR; DiNardo CD; Kadia TM; Yilmaz M; Borthakur G; Alvarado Y; McCue D; McCue D; Kantarjian HM; Ravandi F
Leuk Lymphoma; 2024 Mar; 65(3):378-382. PubMed ID: 38054837
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the efficacy and safety of arsenic trioxide dosing in obese patients with acute promyelocytic leukemia.
Barsoum B; Henneman A; Ahmad S; Ghiuzeli C
Leuk Lymphoma; 2021 Mar; 62(3):703-708. PubMed ID: 33107373
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia.
Breccia M; Cicconi L; Minotti C; Latagliata R; Giannì L; Lo-Coco F
Haematologica; 2011 Sep; 96(9):1390-1. PubMed ID: 21659361
[No Abstract] [Full Text] [Related]
13. The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
Ghiuzeli CM; Stýblo M; Saunders J; Calabro A; Budman D; Allen S; Devoe C; Dhingra R
Leuk Lymphoma; 2022 Mar; 63(3):653-663. PubMed ID: 34689693
[TBL] [Abstract][Full Text] [Related]
14. Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome.
Ueda K; Nagai S; Miyashita SI; Kaise T; Ichikawa M; Kumano K; Hangaishi A; Nannya Y; Kurokawa M
Leuk Res; 2010 Jan; 34(1):e25-6. PubMed ID: 19747729
[No Abstract] [Full Text] [Related]
15. Differentiation syndrome and coagulation disorder - comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia.
Luo JS; Zhang XL; Huang DP; Chen YQ; Wan WQ; Mai HR; Chen HQ; Wen H; Liu RY; Chen GH; Li Y; Luo XQ; Tang YL; Huang LB
Ann Hematol; 2023 Jul; 102(7):1713-1721. PubMed ID: 37199788
[TBL] [Abstract][Full Text] [Related]
16. Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it cost-effective?
Yilmaz U; Eskazan AE
Cancer; 2020 Jan; 126(2):256-259. PubMed ID: 31714587
[No Abstract] [Full Text] [Related]
17. Optical neuropathy possibly related to arsenic during acute promyelocytic leukemia treatment.
Thery JC; Jardin F; Massy N; Massy J; Stamatoullas A; Tilly H
Leuk Lymphoma; 2008 Jan; 49(1):168-70. PubMed ID: 18203030
[No Abstract] [Full Text] [Related]
18. Successful post-remission therapy with a combination of all-trans retinoic acid and arsenic trioxide in an elderly Japanese patient newly diagnosed with acute promyelocytic leukemia.
Kobayashi Y; Hatta Y; Ishizuka H; Hirabayashi Y; Tanaka T; Takei K; Takeuchi J
Int J Hematol; 2010 Jan; 91(1):152-3. PubMed ID: 20033799
[No Abstract] [Full Text] [Related]
19. What is the standard regimen for patients with acute promyelocytic leukemia?
Lo-Coco F; Cicconi L
Curr Hematol Malig Rep; 2014 Jun; 9(2):138-43. PubMed ID: 24729066
[TBL] [Abstract][Full Text] [Related]
20. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.
Look AT
J Natl Cancer Inst; 1998 Jan; 90(2):86-8. PubMed ID: 9450562
[No Abstract] [Full Text] [Related]
[Next] [New Search]
